# US 2019/0240186 A1 · Gold nanoparticle based formulation for use in cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0240186 A1
- Document ID: US20190240186A1
- Status: Published application
- Kind: A1
- Application number: 16/344,519
- Filed: 2017-10-23
- Published: 2019-08-08
- Earliest claimed: 2016-10-25
- Assignees: Council of Scientific and Industrial Research
- Applicants: Council of Scientific & Industrial Research
- Inventors: Rajesh Kotcherlakota; Sudip Mukherjee; Chitta Ranjan Patra; Vijaya Gopal
- Web page: https://patentgrep.com/patent/US20190240186A1

## CPC

- A61K 31/351: not condensed with another ring
- A61K 31/24: having an amino or nitro group
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 33/242: Gold; Compounds thereof
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 35/00: Antineoplastic agents
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 33/243: Platinum; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The current invention relates to development of new formulation containing gold nanoparticles (AuNPs) with bi-functional recombinant fusion proteins TRAF(C) for the delivery of anticancer drugs and nucleic acids to HER2+ cancers. Using the combinatorial approach, we designed gold nanoparticle-based targeted drug delivery system (TDDS) or (Au-TR-DX-si) by combining AuNPs with bi-functional recombinant fusion protein TRAF(C) (TR), doxorubicin (DX) and siRNA (si). The recombinant protein based gold nanoparticles formulations are stable and homogenous as revealed by several physicochemical studies. In addition, the engineered fusion protein TRAF (C) has the ability to target selectively to HER2+ receptors overexpressed in ovarian cancer cells (SK-OV-3).

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

A nanoformulation for targeted treatment of cancer cells expressing HER2+ receptors and delivery of an anticancer drug to the cancer cells, the nanoformulation comprising:
a. a plurality of gold nanoparticles (AuNP);
b. a bi-functional engineered recombinant fusion protein TRAF(C);
c. an anticancer drug; and
d. a nucleic acid;
wherein the bi-functional engineered recombinant fusion protein is conjugated to a surface of the gold nanoparticles (AuNP) using a reactive thiol moiety by introducing a C-terminal cysteine.

### Claim 14 (depends on 13)

The nanoformulation of claim 13, wherein a size of the gold nanoparticles is in the range of 10-100 nm.

### Claim 15 (depends on 13)

The nanoformulation of claim 13, wherein the anticancer drug is selected from the group consisting of doxorubicin, gemcitabine, cisplatin, and methotrexate.

### Claim 16 (depends on 15)

The nanoformulation of claim 15, wherein the anticancer drug is doxorubicin.

### Claim 17 (depends on 16)

The nanoformulation of claim 16, wherein a dose of doxorubicin is in the range of 0.1 to 2.5 mg/kg.

### Claim 18 (depends on 13)

The nanoformulation of claim 13, wherein the nucleic acid is erbB2 siRNA of SEQ ID NO: 6.

### Claim 19 (depends on 18)

The nanoformulation of claim 18, wherein a dose of siRNA is in the range of 0.1 to 0.25 mg/kg.

### Claim 20 (depends on 13)

The nanoformulation of claim 13, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, melanoma, glioma, and prostate cancer.

### Claim 21 (depends on 13)

A pharmaceutical composition comprising a therapeutic amount of the nanoformulation of claim 13.

### Claim 22 (depends on 13)

A method of treating cancer cells expressing HER2+ receptors, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of the nanoformulation of claim 13.

### Claim 23 (depends on 22)

The method of treating cancer cells of claim 22, wherein the nanoformulation is administered by oral, intravenous, intramuscular, or subcutaneous route.

### Claim 24 (depends on 13)

A process for preparation of the nanoformulation of claim 13, the process comprising:
(i) conjugating freshly prepared AuNPs with recombinant fusion protein TRAF(C) to obtain a conjugate;
(ii) incubating the conjugate obtained in (i) for 30 min at room temperature and constantly stirring to form an Au-TR complex;
(iii) conjugating doxorubicin (DX) to the Au-TR complex obtained in (ii) and incubating for 30 mins at room temperature to obtain an intermediate conjugate;
(iv) centrifuging the intermediate conjugate obtained in (iii) at 15,000 rpm for 45 min at 19-21° C. to form an Au-TR-DX complex;
(v) incubating the Au-TR-DX complex obtained in (iv) with a 5:1 mole ratio of siRNA for 30 minutes to obtain the nanoformulation.
